

Rupert Handgretinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10172115/publications.pdf>

Version: 2024-02-01

175
papers

5,057
citations

101543

36
h-index

102487

66
g-index

180
all docs

180
docs citations

180
times ranked

6943
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 4381-4389.	1.6	478
2	HLA-haploidentical stem cell transplantation after removal of $\hat{I}\hat{I}^2+$ T and B cells in children with nonmalignant disorders. <i>Blood</i> , 2014, 124, 822-826.	1.4	385
3	Outcome of children with acute leukemia given HLA-haploidentical HSCT after $\hat{I}\hat{I}^2$ T-cell and B-cell depletion. <i>Blood</i> , 2017, 130, 677-685.	1.4	261
4	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 521-534.	2.4	168
5	Pure red cell aplasia. <i>British Journal of Haematology</i> , 2000, 111, 1010-1022.	2.5	161
6	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2018, 33, 937-948.e8.	16.8	142
7	KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. <i>Blood</i> , 2014, 124, 2744-2747.	1.4	132
8	Exploitation of natural killer cells for the treatment of acute leukemia. <i>Blood</i> , 2016, 127, 3341-3349.	1.4	130
9	Isolation of Highly Purified Autologous and Allogeneic Peripheral CD34+ Cells Using the CliniMACS Device. <i>Stem Cells and Development</i> , 1999, 8, 209-218.	1.0	129
10	Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. <i>Blood</i> , 2015, 125, 1986-1994.	1.4	127
11	Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. <i>Haematologica</i> , 2014, 99, 1212-1219.	3.5	125
12	Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. <i>JAMA Pediatrics</i> , 2021, 175, 586.	6.2	124
13	The potential role of $\hat{I}\hat{I}^2$ T cells after allogeneic HCT for leukemia. <i>Blood</i> , 2018, 131, 1063-1072.	1.4	94
14	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 12-24.	2.4	94
15	Childhood supratentorial ependymomas with <i>YAP1</i> â€MAML1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. <i>Brain Pathology</i> , 2019, 29, 205-216.	4.1	75
16	Pure red cell aplasia. <i>British Journal of Haematology</i> , 2000, 111, 1010-1022.	2.5	73
17	Negative depletion of CD3+ and TcR $\hat{I}\hat{I}^2+$ T cells. <i>Current Opinion in Hematology</i> , 2012, 19, 434-439.	2.5	73
18	New Approaches to Graft Engineering for Haploidentical Bone Marrow Transplantation. <i>Seminars in Oncology</i> , 2012, 39, 664-673.	2.2	72

#	ARTICLE	IF	CITATIONS
19	The German National Registry of Primary Immunodeficiencies (2012–2017). <i>Frontiers in Immunology</i> , 2019, 10, 1272.	4.8	71
20	Feasibility and Outcome of Reduced-Intensity Conditioning in Haploidentical Transplantation. <i>Annals of the New York Academy of Sciences</i> , 2007, 1106, 279-289.	3.8	66
21	Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. <i>Blood Cancer Journal</i> , 2020, 10, 77.	6.2	65
22	High Local Concentrations of Intra-dermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa. <i>Molecular Therapy</i> , 2015, 23, 1368-1379.	8.2	64
23	Increased susceptibility of <i>ifn-γ</i> -treated neuroblastoma cells to lysis by lymphokine-activated killer cells: Participation of ICAM-1 induction on target cells. <i>International Journal of Cancer</i> , 1991, 47, 527-532.	5.1	58
24	Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cell-mediated cytotoxicity against neuroblastoma <i>in vitro</i> and <i>in vivo</i> . <i>Cytotherapy</i> , 2015, 17, 601-612.	0.7	57
25	Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1005-1012.	2.0	55
26	GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. <i>Oncotarget</i> , 2020, 9, 16833-16845.	4.6	54
27	Inhibitory MHC class I receptors on $\gamma\delta$ T cells in tumour immunity and autoimmunity. <i>Trends in Immunology</i> , 2000, 21, 187-191.	7.5	53
28	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	3.5	51
29	Monocyte-Induced Development of Th17 Cells and the Release of S100 Proteins Are Involved in the Pathogenesis of Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2014, 193, 3355-3365.	0.8	49
30	Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. <i>Oncotarget</i> , 2015, 4, e1014760.	4.6	49
31	Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors. <i>Molecular and Cellular Pediatrics</i> , 2018, 5, 9.	1.8	49
32	Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 681-688.	2.8	47
33	$\gamma\delta$ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay. <i>Frontiers in Immunology</i> , 2014, 5, 618.	4.8	46
34	Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment. <i>Journal of Clinical Oncology</i> , 2015, 33, 3029-3029.	1.6	45
35	Human Peripheral CD4+ V α 1+ $\gamma\delta$ T Cells Can Develop into $\gamma\delta$ T Cells. <i>Frontiers in Immunology</i> , 2014, 5, 645.	4.8	40
36	Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects <i>in vivo</i> . <i>Oncotarget</i> , 2017, 6, e1323161.	4.6	39

#	ARTICLE	IF	CITATIONS
37	CD34 ⁺ selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 180, 90-99.	2.5	39
38	Chronic graft-versus-host-disease in CD34 ⁺ -humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease. <i>Journal of Autoimmunity</i> , 2015, 62, 55-66.	6.5	38
39	Collagen VII Half-Life at the Dermal-Epidermal Junction Zone: Implications for Mechanisms and Therapy of Genodermatoses. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1116-1123.	0.7	38
40	Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34 ⁺ HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin. <i>Scientific Reports</i> , 2020, 10, 10133.	3.3	38
41	CD133-Positive Hematopoietic Stem Cells: From Biology to Medicine. <i>Advances in Experimental Medicine and Biology</i> , 2013, 777, 99-111.	1.6	34
42	Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β^0 -Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34 ⁺ Hematopoietic Stem and Progenitor Cells. <i>Blood</i> , 2020, 136, 3-4.	1.4	34
43	Human $\gamma\delta$ T Cells From G-CSF-Mobilized Donors Retain Strong Tumoricidal Activity and Produce Immunomodulatory Cytokines After Clinical-Scale Isolation. <i>Journal of Immunotherapy</i> , 2005, 28, 73-78.	2.4	30
44	Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report. <i>Journal of Translational Medicine</i> , 2018, 16, 23.	4.4	30
45	Treatment of graft failure with α -TBI-based reconditioning and haploidentical stem cells in paediatric patients. <i>British Journal of Haematology</i> , 2016, 175, 115-122.	2.5	29
46	Immune Response of Human Propagated $\gamma\delta$ -T-Cells to Neuroblastoma Recommend the V β 1 ⁺ Subset for $\gamma\delta$ -T-cell-based Immunotherapy. <i>Journal of Immunotherapy</i> , 2008, 31, 896-905.	2.4	28
47	Tumor-priming converts NK cells to memory-like NK cells. <i>Onc Immunology</i> , 2017, 6, e1317411.	4.6	28
48	Haploidentical stem cell transplantation in DOCK8 deficiency â€” Successful control of pre-existing severe viremia with a TCR $\alpha\beta$ /CD19-depleted graft and antiviral treatment. <i>Clinical Immunology</i> , 2014, 152, 111-114.	3.2	27
49	G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients. <i>British Journal of Haematology</i> , 2019, 186, 60-71.	2.5	27
50	Results of a multicenter phase I/II trial of TCR $\alpha\beta$ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 423-430.	2.4	27
51	NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	2.2	26
52	Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1003-1013.	4.2	26
53	CRISPR/Cas9-modified hematopoietic stem cellsâ€”present and future perspectives for stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1940-1950.	2.4	26
54	Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy. <i>Cytotherapy</i> , 2019, 21, 973-986.	0.7	25

#	ARTICLE	IF	CITATIONS
55	Targeting hedgehog signalling by arsenic trioxide reduces cell growth and induces apoptosis in rhabdomyosarcoma. <i>International Journal of Oncology</i> , 2016, 48, 801-812.	3.3	24
56	Transcriptomic profile of cystic fibrosis patients identifies type I interferon response and ribosomal stalk proteins as potential modifiers of disease severity. <i>PLoS ONE</i> , 2017, 12, e0183526.	2.5	23
57	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. <i>Blood Advances</i> , 2022, 6, 1004-1014.	5.2	22
58	Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy. <i>BMC Cancer</i> , 2019, 19, 1172.	2.6	21
59	Both mature KIR+ and immature KIR ^{hi} NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice. <i>Blood</i> , 2014, 124, 3914-3923.	1.4	20
60	Rapid generation of NY-ESO-1-specific CD4 ⁺ T _H 1 cells for adoptive T-cell therapy. <i>Oncotargets and Therapy</i> , 2015, 4, e1002723.	4.6	20
61	Enzymatic characterization of novel arylsulfatase A variants using human arylsulfatase A-deficient immortalized mesenchymal stromal cells. <i>Human Mutation</i> , 2017, 38, 1511-1520.	2.5	20
62	LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis. <i>Blood</i> , 2019, 134, 1159-1175.	1.4	20
63	Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial. <i>Leukemia</i> , 2020, 34, 613-624.	7.2	19
64	Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody. <i>Molecular Therapy</i> , 2016, 24, 1634-1643.	8.2	18
65	Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting. <i>Oncotargets and Therapy</i> , 2021, 10, .	4.6	16
66	Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3567-3578.	2.0	14
67	Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches. <i>Blood Reviews</i> , 2020, 40, 100641.	5.7	14
68	A case series of children and young people admitted to a tertiary care hospital in Germany with COVID-19. <i>BMC Infectious Diseases</i> , 2021, 21, 133.	2.9	14
69	Long-Term Clinical Outcome and Prognostic Factors of Children and Adolescents with Localized Rhabdomyosarcoma Treated on the CWS-2002P Protocol. <i>Cancers</i> , 2022, 14, 899.	3.7	14
70	Increase of Intermediate Monocytes in Graft-versus-Host Disease: Correlation with MDR1+Th17.1 Levels and the Effect of Prednisolone and 1 α ,25-Dihydroxyvitamin D3. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2057-2064.	2.0	13
71	Defibrotide for the Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 2 Pediatric Patients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 622-625.	1.3	13
72	Myeloid-Derived Suppressor Cells Dampen Airway Inflammation Through Prostaglandin E2 Receptor 4. <i>Frontiers in Immunology</i> , 2021, 12, 695933.	4.8	13

#	ARTICLE	IF	CITATIONS
73	In Vitro Induction of Lymphokine-Activated Killer (Lak) Activity in Patients with Neuroblastoma. <i>Pediatric Hematology and Oncology</i> , 1989, 6, 307-317.	0.8	11
74	Improved selectivity of mIBG uptake into neuroblastoma cells in vitro and in vivo by inhibition of organic cation transporter 3 uptake using clinically approved corticosteroids. <i>Nuclear Medicine and Biology</i> , 2016, 43, 543-551.	0.6	11
75	Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent Manner. <i>Frontiers in Immunology</i> , 2019, 10, 1542.	4.8	11
76	TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: First Results of a Prospective Multicenter Phase I/II Clinical Trial. <i>Blood</i> , 2016, 128, 389-389.	1.4	11
77	Correlation between positron emission tomography and Cerenkov luminescence imaging <i>in vivo</i> and <i>ex vivo</i> using ⁶⁴ Cu-labeled antibodies in a neuroblastoma mouse model. <i>Oncotarget</i> , 2016, 7, 67403-67411.	1.8	11
78	Effects of granulocytes on human neuroblastoma cells measured by chemiluminescence and chromium-51 release assay. <i>Luminescence</i> , 1989, 3, 93-96.	0.0	10
79	Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 690467.	4.8	10
80	Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines. <i>PLoS ONE</i> , 2017, 12, e0178857.	2.5	10
81	Indications and Donor Selections for Allogeneic Stem Cell Transplantation in Children with Hematologic Malignancies. <i>Pediatric Clinics of North America</i> , 2008, 55, 71-96.	1.8	9
82	Synthesis and biological effects of new hybrid compounds composed of benzylguanidines and the alkylating group of busulfan on neuroblastoma cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2728-2733.	2.2	9
83	Transplantation of Tc ^{99m} /CD19 Depleted Stem Cells From Haploidentical Donors: Robust Engraftment and Rapid Immune Reconstitution In Children with High Risk Leukemia. <i>Blood</i> , 2011, 118, 1005-1005.	1.4	9
84	Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 402-411.	2.0	8
85	Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas. <i>International Journal of Oncology</i> , 2016, 49, 2135-2146.	3.3	8
86	Characterization of monocyte subtypes regarding their phenotype and development in the context of graft-versus-host disease. <i>Transplant Immunology</i> , 2018, 50, 48-54.	1.2	8
87	Allogeneic hematopoietic stem cell transplantation in two brothers with DNA ligase IV deficiency: a case report and review of the literature. <i>BMC Pediatrics</i> , 2019, 19, 346.	1.7	8
88	Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma – a case report. <i>International Journal of Hyperthermia</i> , 2020, 37, 55-65.	2.5	8
89	Fulminant <i>Rhizomucor pusillus</i> mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature. <i>Medical Mycology Case Reports</i> , 2021, 32, 4-9.	1.3	8
90	Combinatorial Targeting of Multiple Shared Antigens By Adapter-CAR-T Cells (aCAR-Ts) Allows Target Cell Discrimination and Specific Lysis Based on Differential Expression Profiles. <i>Blood</i> , 2018, 132, 4543-4543.	1.4	8

#	ARTICLE	IF	CITATIONS
91	Emerging role of immunotherapy for childhood cancers. <i>Chinese Clinical Oncology</i> , 2018, 7, 14-14.	1.2	8
92	A Mutation-Agnostic Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy. <i>CRISPR Journal</i> , 2022, 5, 66-79.	2.9	8
93	Somatic Reversion of a Novel IL2RG Mutation Resulting in Atypical X-Linked Combined Immunodeficiency. <i>Genes</i> , 2022, 13, 35.	2.4	8
94	Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO). <i>Blood</i> , 2019, 134, 1294-1294.	1.4	7
95	Preemptive administration of human $\alpha\beta$ T cell receptor-targeting monoclonal antibody GZ- $\alpha\beta$ TCR potently abrogates aggressive graft-versus-host disease in vivo. <i>Annals of Hematology</i> , 2015, 94, 1907-1919.	1.8	6
96	Association analysis between SUFU polymorphism rs17114808 and acute graft versus host disease after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 377-382.	2.4	6
97	Matched versus Haploidentical Hematopoietic Stem Cell Transplantation as Treatment Options for Primary Immunodeficiencies in Children. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 71.e1-71.e12.	1.2	6
98	Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease. <i>Stem Cells and Development</i> , 2021, 30, 234-246.	2.1	6
99	Universal Gene Correction Approaches for β -hemoglobinopathies Using CRISPR-Cas9 and Adeno-Associated Virus Serotype 6 Donor Templates. <i>CRISPR Journal</i> , 2021, 4, 207-222.	2.9	6
100	Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10056-10056.	1.6	6
101	Blinatumomab use in pediatric patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) from an open-label, multicenter, expanded access study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10530-10530.	1.6	6
102	Use of a Fc-Optimized CD19 Antibody for Treatment of MRD in Pediatric Patients with B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 581-581.	1.4	6
103	Hematopoietic Stem Cell Transplantation with Mesenchymal Stromal Cells in Children with Metachromatic Leukodystrophy. <i>Stem Cells and Development</i> , 2022, 31, 163-175.	2.1	6
104	Expression of KIR2DS1 does not significantly contribute to NK cell cytotoxicity in HLA-C1/C2 heterozygous haplotype B donors. <i>International Immunology</i> , 2017, 29, 423-429.	4.0	5
105	Ex vivo expansion of autologous, donor-derived NK-, $\alpha\beta$ T-, and cytokine induced killer (CIK) cells post haploidentical hematopoietic stem cell transplantation results in increased antitumor activity. <i>Bone Marrow Transplantation</i> , 2019, 54, 727-732.	2.4	5
106	<p>Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3439-3451.	4.3	5
107	ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL. <i>Bone Marrow Transplantation</i> , 2019, 54, 689-693.	2.4	5
108	Fast enzymatic synthesis of n.c.a. 18 F-fluorodopamine (FDA) from n.c.a. 18 F-DOPA and the fate of 18 F-DOPA and 18 F-FDA in neuroblastoma and Caki cells after their uptake. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 438-447.		5

#	ARTICLE	IF	CITATIONS
109	Enriched Bone Marrow Derived Disseminated Neuroblastoma Cells Can Be a Reliable Source for Gene Expression Studies—A Validation Study. PLoS ONE, 2015, 10, e0137995.	2.5	5
110	Safety and Feasibility of Posaconazole as Oral Antifungal Prophylaxis In Pediatric Patients Under 12 Years of Age Following Allogeneic Stem Cell Transplantation.. Blood, 2010, 116, 1308-1308.	1.4	5
111	How an accidental discovery paved the way for the treatment of complicated infantile haemangiomas. Acta Paediatrica, International Journal of Paediatrics, 2014, 103, 896-897.	1.5	4
112	No association between the presence of killer-cell immunoglobulin-like receptor genes and susceptibility to childhood ALL. Blood, 2015, 125, 3355-3357.	1.4	4
113	Establishment and Characterization of a Sclerosing Spindle Cell Rhabdomyosarcoma Cell Line with a Complex Genomic Profile. Cells, 2020, 9, 2668.	4.1	4
114	Arginase 1⁺ ILâ€10⁺ polymorphonuclear myeloidâ€derived suppressor cells are elevated in patients with active pemphigus and correlate with an increased Th2/Th1 response. Experimental Dermatology, 2021, 30, 782-791.	2.9	4
115	Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts. Bone Marrow Transplantation, 2019, 54, 53-62.	2.4	3
116	Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1089-1100.	2.5	3
117	Hematopoietic Stem Cell Transplantation for Patients with Autosomal Recessive Complete INF-Î» Receptor 2 Deficiency: Experience in Oman. Transplantation and Cellular Therapy, 2021, 27, 881.e1-881.e5.	1.2	3
118	High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study. Blood, 2018, 132, 1375-1375.	1.4	3
119	Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning. Blood, 2018, 132, 604-604.	1.4	3
120	Germline Genetic Variation in IKZF1 and Predisposition to Childhood Acute Lymphoblastic Leukemia. Blood, 2016, 128, LBA-2-LBA-2.	1.4	3
121	ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T) Tj ETQq1 1 0.784314 rgBT / leukemia (r/r ALL).. Journal of Clinical Oncology, 2016, 34, TPS7075-TPS7075.	1.6	3
122	Interaction of arsenic trioxide and etoposide in Ewing sarcoma cell lines. Oncology Reports, 2020, 43, 337-345.	2.6	3
123	A Prospective, Multicenter Study of Closed System Extracorporeal Photopheresis for Children With Steroid-Refractory Acute Graft-Versus-Host Disease. Transplantation and Cellular Therapy, 2022, , .	1.2	3
124	Two-cavities approach for resection of pediatric abdominal neuroblastic tumors: experience of a national reference pediatric onco-surgical center. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1485-1493.	2.5	3
125	Expression of GD3 disialoganglioside antigen on peripheral T-lymphocytes in patients with disseminated malignant melanoma. Experimental Dermatology, 1997, 6, 64-69.	2.9	2
126	Comparative analysis of lentiviral gene transfer approaches designed to promote fetal hemoglobin production for the treatment of Î²-hemoglobinopathies. Blood Cells, Molecules, and Diseases, 2020, 84, 102456.	1.4	2

#	ARTICLE	IF	CITATIONS
127	RNA ImmunoGenic Assay: Simple method for detecting immunogenicity of in vitro transcribed mRNA. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e79.	0.9	2
128	Removal of CD276+ cells from haploidentical memory T-cell grafts significantly lowers the risk of GVHD. <i>Bone Marrow Transplantation</i> , 2021, 56, 2336-2354.	2.4	2
129	Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO). <i>Blood</i> , 2020, 136, 24-25.	1.4	2
130	Comparison Between Related T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (TCD-Haplo) and Umbilical Cord Blood Transplantation (UCBT) in Pediatric Patients with Acute Leukemia, a Eurocord, PDWP-EBMT Study. <i>Blood</i> , 2014, 124, 1215-1215.	1.4	2
131	Fetomaternal Microchimerism Is Associated with Better Outcome in Haploidentical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 1242-1242.	1.4	2
132	RNA ImmunoGenic Assay: A Method to Detect Immunogenicity of in vitro Transcribed mRNA in Human Whole Blood. <i>Bio-protocol</i> , 2020, 10, e3850.	0.4	2
133	Could (should) we abandon total body irradiation for conditioning in children with leukemia. <i>Blood Reviews</i> , 2022, 56, 100966.	5.7	2
134	Metronomic oral maintenance chemotherapy in patients with localized high-risk rhabdomyosarcoma (RMS) and RMS-like tumors: A report from a randomized, multicenter, phase III trial CWS-2007HR.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10033-10033.	1.6	2
135	Rapid method for purification of CD56+ natural killer cells with preferential enrichment of the CD56bright+ subset. <i>Journal of Clinical Laboratory Analysis</i> , 1994, 8, 443-446.	2.1	1
136	<p>Antiemetic Prophylaxis with Fosaprepitant and 5-HT<sub>3</sub>-Receptor Antagonists in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3915-3927.	4.3	1
137	A New Dosing Scheme of ATG-F Prevents Rejection and Maintains Immune Recovery in Haploidentical T and B Cell Depleted Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4154-4154.	1.4	1
138	Alternative Donor Stem Cell Transplantation In Aplastic Anemias and Refractory Cytopenias Is Save and Feasible With T- and B-Cell Depleted Haploidentical Grafts. <i>Blood</i> , 2013, 122, 4573-4573.	1.4	1
139	Leukemia Related Co-Stimulation / Co-Inhibition Predict T-Cell Attack of Acute Lymphoblastic Leukemia Mediated By Blinatumomab. <i>Blood</i> , 2015, 126, 3764-3764.	1.4	1
140	Adoptive Transfer of Hexon-Specific T-Cells as a Treatment of Adenovirus Reactivation Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 796-796.	1.4	1
141	Effect of the HDAC Inhibitor SAHA on the Immunomodulatory Properties of MSC and Tumor Stroma Cells.. <i>Blood</i> , 2010, 116, 2592-2592.	1.4	1
142	Interventional Intensification of Chemotherapy Prior to Hematopoietic Stem Cell Transplantation Reduces Residual Leukemia but Does Not Improve Survival in Children with Relapsed Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 61-61.	1.4	1
143	Introducing isotonic fluids into pediatric oncology. <i>Pediatric Hematology and Oncology</i> , 2021, , 1-8.	0.8	1
144	The role of $\hat{1}^3$ T cells in the context of allogeneic stem cell transplantation. <i>Exploration of Immunology</i> , 0, , 157-167.	0.3	1

#	ARTICLE	IF	CITATIONS
145	Haploidentical Allogeneic Hematopoietic Cell Transplantation in Adults with CD3/CD19-Depleted Grafts after Reduced-Intensity Conditioning: A Phase I/II Study.. Blood, 2007, 110, 3072-3072.	1.4	0
146	Hematopoietic Progenitor Cell Transplantation from Parental Donors for Children with Sickle Cell Anemia and Stroke.. Blood, 2007, 110, 3393-3393.	1.4	0
147	Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Clinical Outcome and Immune Reconstitution.. Blood, 2009, 114, 1203-1203.	1.4	0
148	High Progenitor Cell Frequency at Diagnosis Predicts High Minimal residual Disease Level in Childhood ALL.. Blood, 2009, 114, 4705-4705.	1.4	0
149	Long Term Survival and Relapse Rate After Transplantation of Highly T and B Cell Depleted Stem Cells From Alternative Donors in Pediatric Patients with Acute Lymphatic Leukemia.. Blood, 2009, 114, 4333-4333.	1.4	0
150	Improved T Cell Recovery After Transplantation of CD3/CD19 depleted Haploidentical Stem Cell Grafts in Pediatric Patients.. Blood, 2009, 114, 4652-4652.	1.4	0
151	Allogeneic Stem Cell Transplantation for Acquired Aplastic Anemia: Better Outcome with Bone Marrow as Compared to Peripheral Blood in HLA-Matched Sibling Donor Transplantation and Improved Outcome Over Time After Matched Unrelated Donor Transplantation. A Retrospective Analysis of Transplants Reported to the German Registry for Stem Cell Transplantation (DRST).. Blood, 2009, 114, 876-876.	1.4	0
152	Use of IL15 Stimulated, CD3/19 Depleted Transplants From Haploidentical Donors In Pediatric Malignancies. Blood, 2010, 116, 3548-3548.	1.4	0
153	Transient but Reversible Activation Defect of T-Cell Responses Against Cytomegalovirus and Adenovirus through Immunosuppression with Calcineurin Inhibitors.. Blood, 2010, 116, 4542-4542.	1.4	0
154	Allogeneic Hematopoietic Stem Cell Transplantation (SCT) In Children with ALL: Outcome of Matched Sibling Donor SCT (MSD-SCT) Is Equivalent to Unrelated Well Matched Donor HSCT (MD-HSCT) A Report From the Prospective International Multicenter Trial ALL-SCT-BFM 2003. Blood, 2010, 116, 530-530.	1.4	0
155	Haploidentical Stem Cell Transplantation for Children with High-Risk Leukemia In Chile: Report of the First 15 Cases.. Blood, 2010, 116, 4581-4581.	1.4	0
156	Patterns of HLA-DR Surface Expression on CD14+ Monocytes During Adverse Events After Hematopoietic Stem Cell Transplantation.. Blood, 2010, 116, 1499-1499.	1.4	0
157	Adoptive Transfer of EBNA1-Specific T-Cells as a Treatment of Epstein-Barr-Virus Reactivation Following Allogeneic Stem Cell Transplantation. Blood, 2010, 116, 2342-2342.	1.4	0
158	Reduced Risk of Relapse In Pediatric ALL After Haploidentical Transplantation of T-Cell Depleted Grafts From KIR Haplotype B Donors.. Blood, 2011, 118, 4133-4133.	1.4	0
159	NK Cell Activity Influences Long Term Outcome of Pediatric Leucemias After T Cell Depleted Stem Cell Transplantation,. Blood, 2011, 118, 4141-4141.	1.4	0
160	KIR Haplotype B Donors but Not KIR-Ligand Mismatch Result in a Reduced Risk of Relapse After Haploidentical Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning and a CD3/CD19 Depleted Graft.. Blood, 2012, 120, 3101-3101.	1.4	0
161	Detection of Th1 Driven T-Cell Responses in Peripheral Blood Could Guide Individualized Immunosuppression and Risk of Viral Reactivation Under GvHD Prophylaxis Following Allogeneic Stem Cell Transplantation.. Blood, 2012, 120, 3047-3047.	1.4	0
162	Flow Cytometry Based Chimerism Analysis Can Predict Graft Rejection in Pediatric Patients Receiving HLA Mismatched Stem Cell Transplantation. Blood, 2012, 120, 4156-4156.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Which patients with rhabdomyosarcoma (RMS) do need radiotherapy (RTX)? The long-term results of the CWS studies -81, -86, -91, and -96.. Journal of Clinical Oncology, 2014, 32, 10005-10005.	1.6	0
164	NY-ESO-1 specific CD4 ⁺ T _h 1 cells for immunotherapy of cancer.. Journal of Clinical Oncology, 2014, 32, 3071-3071.	1.6	0
165	Transfer of Ex Vivo Expanded NK and $\gamma\delta$ T Cells from Untouched Posttransplant PBMCs to Clear Minimal Residual Disease in Acute Myeloid Leukemia. Blood, 2014, 124, 5294-5294.	1.4	0
166	Improved Immune Recovery after Transplantation of TCR $\alpha\beta$ /CD19 Depleted Allografts from Haploidentical Donors in Pediatric Patients. Blood, 2014, 124, 852-852.	1.4	0
167	Generation of specific polyclonal and polyfunctional CD4 ⁺ T-helper1 cells against WT-1, MAGE-A3, Survivin and ROR-1 for adoptive T-cell immunotherapy.. Journal of Clinical Oncology, 2015, 33, e14025-e14025.	1.6	0
168	Decentralized Manufacture of TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Grafts for Children within a Multicenter Phase I/II Clinical Trial. Blood, 2016, 128, 2172-2172.	1.4	0
169	Prophylaxis of Chemotherapy-Induced Nausea and Vomiting with Fosaprepitant and Granisetron in Pediatric Patients after Allogeneic HSCT. Blood, 2018, 132, 3388-3388.	1.4	0
170	Invariant Natural Killer T Cells from Donor Lymphocyte Infusions (DLI-iNKTs) Contribute to Anti-Tumor Immunity after Allogeneic Hematopoietic Cell Transplantation. Blood, 2018, 132, 3340-3340.	1.4	0
171	Use of Ex Vivo Graft Manipulation and Posttransplant Cyclophosphamide Result in Low GvHD Rates and Acceptable Engraftment after RIC Regimens in Pediatric Mismatched SCT. Blood, 2019, 134, 3255-3255.	1.4	0
172	Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT. Blood, 2020, 136, 45-47.	1.4	0
173	The role of graft-versus-host disease in the inhibition of normal B-lymphopoiesis and leukemic control of B-lineage acute lymphocytic leukemia after allogeneic stem cell transplantation. Haematologica, 2006, 91, 292B.	3.5	0
174	Hoechst 33342 Staining Identifies the Progenitor Side Population in NOD.Cg-PrkdcscidIL2rgtmWjl/Sz Mice Harboring Pediatric Leukemias. In Vivo, 2015, 29, 661-9.	1.3	0
175	D,L-Methadone enhances the cytotoxic activity of standard chemotherapeutic agents on pediatric rhabdomyosarcoma. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	2.5	0